Psychedelic medicine is having its scientific moment. Most coverage cannot tell breakthrough from press release. Psilosignal can. Every Tuesday, you get the difference, in plain language, with the citations to back it up.
In 2026, more than 1,800 articles will be published about psychedelic medicine. Most will be press releases dressed as journalism. A small fraction will move the science forward. Knowing the difference is a full-time job. Psilosignal does it for you.
Year over year, press coverage of psychedelic medicine has grown 4x. Peer-reviewed publications have grown 1.2x. Psilosignal reads everything in the top line, but writes only about what is actually in the bottom one. Source: PubMed and Google News, 2026.
Every issue follows the same arc: observation, evidence, takeaway. The structure is what makes it readable in five minutes and useful for the rest of the week.
PubMed, ClinicalTrials.gov, FDA filings, EMA notices, conference proceedings, and direct conversations with researchers. So you do not have to.
Press releases get cross-checked against trial data. Hot takes get checked against the underlying paper. Hype gets named as such.
500 to 1,000 words. Charts where they help. Citations always. Written so a curious patient and a working researcher both leave with something useful.
The psychedelic medicine space moves fast and gets reported badly. Psilosignal exists for the readers who cannot afford either problem.
Veterans, those exploring options for treatment-resistant depression, PTSD, stroke recovery, plus the people supporting them. Get clarity on what is available, what is coming, and what is still hype.
LPs, family offices, and operators trying to separate credible early-stage opportunities from PR-driven promotion. We name names, cite sources, and flag what is actually moving.
Neuroscientists, psychiatrists, and trial coordinators who want consolidated weekly updates on protocols, outcomes, and regulatory shifts. No more combing fifteen feeds.
Health journalists, policy thinkers, and the genuinely curious. Accessible explainers grounded in primary research. No woo. No moral panic. Just the work.
Researchers, investors, and patients sharing what Psilosignal actually does for their week.
The only psychedelic newsletter I forward to my entire research team. Domenic does the work of reading the actual papers so we do not have to argue about second-hand summaries.
I run a fund focused on this space. Psilosignal is the first thing I read Tuesday morning. It is the only one I trust to flag a press release dressed up as a breakthrough.
As a veteran exploring trial options, this newsletter cut through more confusion in three issues than six months of forums. Honest, careful, never selling me anything.
Domenic is the co-founder and Chief Operating Officer of Rose Hill Health Holdings, with 11+ years as a senior executive in operationally complex, highly regulated industries. His path into alternative medicine started in 2010 with a seed investment into Evolab, a Denver-based vertically integrated cannabis company, where he served as COO from 2013 to 2018 through the acquisition by Harvest Health and Recreation (HARV: CSE). He went on to lead manufacturing operations at Supreme Cannabis (CSE: FIRE), supported the BLISSCO acquisition, and has worked with national brands including KKE, Monogram, Native Sun, Terps, and Tilt.
Psilosignal exists because he kept watching credible science get crowded out by hot takes, and credible companies get conflated with hype factories. Each Tuesday's issue is built from primary sources: peer-reviewed papers, regulatory filings, trial registries, and direct conversations with the researchers and clinicians shaping the field. The goal is not to be the loudest voice in psychedelic medicine. It is to be the one you trust when the next headline drops.
